Call for patient organization input on certolizumab pegol (Cimzia®) for psoriatic arthritis
Do you have psoriatic arthritis or care for someone who does? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for certolizumab pegol (Cimzia®) for the treatment of psoriatic arthritis (PsA). Certolizumab pegol is indicated for use in combination with methotrexate for reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active psoriatic arthritis who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs). Continue reading →
Today, the “Spotlight on Arthritis Superheroes” is directed on Rheumatoid Arthritis Guy.
RA Guy’s rheumatoid arthritis started when he was in his 20’s. His heels were in pain and his knees creaked. In the winter time, his RA symptoms became worse. In his 30’s, his pain never went away and he was unable to use his knees. Finally, after many visits to a doctor, he came across a rheumatologist who confirmed that he had rheumatoid arthritis.
Since his diagnosis, RA Guy has learned a lot about rheumatoid arthritis.
“I learned what TENS means. I gained weight. I regained the use of my knees. I got on meds. I got off meds. I got back on meds. I started doing yoga. I lost a lot of weight. I started taking hot baths. I started sleeping with wool socks. I started taking lots of NSAIDs. I started having stomach problems. I got depressed. I started wearing ankle braces. I started wearing wrist braces. I got happy. I started meditating. I started writing positive affirmations. I started pacing myself through my day-to-day activities. I went into remission. I came out of remission. I had lots of flares. I started therapy. I started getting early joint damage. I started this blog. Most importantly, I started to learn how to LIVE with rheumatoid arthritis.”
Join RA Guy as he shares his ups and downs and continues his journey through chronic pain and debilitating inflammation. Our favourite part about his blogs is that he uses humor to shed light onto matters that others may consider serious. Continue reading →
One of the main goals of the PRECISION project, showcased in July’s issue of JointHealth™ monthly, is to enable clients to lead a healthy life in the context of their chronic disease. Besides medical adherence, rheumatologists should also express concern about their patient’s sex life and ask, “How’s your sex life?”
In an interview with The Rheumatologist, Alex Shteynshlyuger, MD, a New York urologist, said that more than half of all rheumatoid arthritis patients have difficulties with sex and yet the topic gets little attention from rheumatologists.
The Arthritis Broadcast Network would like to share with you below Chronic Marriage’s blog post titled “In Sickness As in Health”, where Helena shares her response to a book on navigating marriage (and life) with chronic pain.
In Sickness As In Health is full of hope as well as lessons learned; a breath of fresh air for those of us desiring new and sound strategies for navigating marriage (and life) with chronic illness.
Co-author Barbara Kivowitz has herself lived with chronic pain since 1999 so she writes from experience and with authority. She is also a psychotherapist, organizational consultant and advisor to several health systems. In other words, she knows her stuff.
The book is broken down into three parts and 12 chapters:
JointHealth™ monthly – May, 2014: Three Women Who “Rock” Arthritis
Women and arthritis are strongly linked: Two out of three living with the disease are women; sixty percent of Canada’s medical students are women, and they will become doctors providing care to women with arthritis; women have led a number of significant advances in clinical arthritis research in Canada.
In this issue of JointHealth™ monthly, Arthritis Consumer Experts (ACE) is proud to profile three women who “rock” the arthritis world. You will find the following interviews:
Dr. Linda Li on arthritis knowledge and exercise in the digital age
Dr. Janis McCaffrey on being a “Doctor Mom” living with lupus
Dr. Julia Alleyne on sports and exercise
This issue’s “Health Happenings” highlights ACE’s latest initiative, Canada’s Best Workplaces for Employees Living with Arthritis competition, and how your company can qualify for this award.
Photo Courtesy of Stuart Miles via freedigitalphotos.net
Reflecting on how few rheumatologists there are in Canada and how many people live with arthritis, Fran counts herself among the select few—a jackpot winner, in a way—for having a rheumy.
I am one of the fortunate ones. There have been many days of late when I didn’t feel so lucky with an inflammatory disease that likes to highjack my life. But apparently I should count myself among the select few because I have a rheumatologist I am able to see for regular checkups or call on in crisis (depending what’s brewing with my ankylosing spondylitis). Continue reading →
The JointHealth™ Report Card and Arthritis Medications Guide issue
While there are no cures for arthritis, scientific advances and improved treatments, along with a better understanding of combination medication therapy, are allowing people with arthritis to live healthier, more productive lives. In particular, advances in the area of disease-modifying anti-rheumatic medications (or “DMARDs”) and biologic response modifiers (or “biologics”) have radically changed health outcomes—for the better—of thousands of people living with a number of the more than 100 types of arthritis.
To ensure that all Canadians have access to the medications they need to treat their arthritis, Arthritis Consumer Experts (ACE) created the first JointHealth™ Report Card on Provincial Formulary Reimbursements for Biologic Response Modifiers in 2007. Serving as a way to keep Canadians aware of how well their province compares to the rest of Canada in its cost coverage of medications, the Report Card ranks publicly funded medication formularies based on the number of medically necessary biologic arthritis medications they list.
The Report Card is available online at jointhealth.org and updated monthly. Once a year, it is printed and distributed to JointHealth™ monthly readers and subscribers, elected officials, arthritis specialists and healthcare professionals across Canada.
A chart listing important information about the medications used to treat arthritis in Canada, called the JointHealth™ Arthritis Medications Guide.
An interview with Dr. Kam Shojania of the Arthritis Research Centre of Canada, in which he tells us about emerging medications for treating the most common forms of inflammatory and autoimmune arthritis.
Details of ACE’s campaign to raise awareness about subsequent entry biologics (SEBs) in BC, Alberta, and Ontario.
Information about exciting new research that was presented late last year in an annual conference that brings together researchers from around the world.
Spending time down south in the Florida sun sure sounds like a cure-all for ankylosing spondylitis (AS) and osteoarthritis. However, the reality—for me—is very different. Weeks before we leave on our annual sojourn, I fantasize about how my various aches and pains will miraculously disappear once my joints are warmed by the sun and surf. I am (obviously) delusional (or seriously in denial) because every year I am sorely disappointed that my AS and osteo fail to give me a break during my winter reprieve. Continue reading →
The 2014 Chinese New Year begins this Friday (January 31). This year will be the Year of the Horse. Your Chinese zodiac is a horse if you were born between the following dates listed on the right side of this page. Continue reading →
With two new medications approved by Health Canada this month, the New Year is looking promising for people who live with certain forms of inflammatory arthritis.
So far in 2014, Health Canada has issued Notices of Compliance (NOCs) for certolizumab pegol (Cimzia®) for the treatment of psoriatic arthritis (January 2) and for the treatment of ankylosing spondylitis (January 15), and ustekinumab (Stelara®) for the treatment of psoriatic arthritis (January 21). Continue reading →